RESPONSE RATES MATTER IN FIRST-LINE ADVANCED NSCLC:
ABRAXANE + CARBOPLATIN DELIVERED
SIGNIFICANTLY SUPERIOR ORR VS PACLITAXEL

RESPONSE RATES MATTER IN FIRST-LINE ADVANCED NSCLC:
ABRAXANE + CARBOPLATIN DELIVERED SIGNIFICANTLY SUPERIOR ORR VS PACLITAXEL

Overall response rate in the ITT population

Advanced Non-Small Cell Lung Cancer (NSCLC) overall response rate in ITT population - chart Advanced Non-Small Cell Lung Cancer (NSCLC) overall response rate in ITT population - chart ITT=intent to treat; ORR=overall response rate; PS=performance status.

National Comprehensive Cancer Network® (NCCN®) 1st-Line Treatment Recommendation1a,b

  • Median duration of response was 6.9 months vs 6.0 months
    (95% CI: 5.6-8.0 months vs 5.6-7.1 months, respectively)
  • No statistically significant difference in overall survival (OS) between ABRAXANE + carboplatin vs paclitaxel injection + carboplatin
    (Median OS 12.1 months vs 11.2 months, P=NS)11
  • Median duration of response was 6.9 months vs 6.0 months
    (95% CI: 5.6-8.0 months vs 5.6-7.1 months, respectively)
  • Median duration of response was 6.9 months vs 6.0 months (95% CI: 5.6-8.0 months vs 5.6-7.1 months, respectively)
  • No statistically significant difference in overall survival (OS) between ABRAXANE + carboplatin vs paclitaxel injection + carboplatin
    (Median OS 12.1 months vs 11.2 months, P=NS)11
  • No statistically significant difference in overall survival (OS) between ABRAXANE + carboplatin vs paclitaxel injection + carboplatin (Median OS 12.1 months vs 11.2 months, P=NS)11

National Comprehensive Cancer Network® (NCCN®) 1st-Line Treatment Recommendation1b,c

  • aFirst-line albumin-bound paclitaxel (ABRAXANE) + carboplatin for PS 0-1 patients with advanced NSCLC and EGFR, ALK, ROS-1, BRAF, and PD-L1 negative or unknown.
  • bCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • cP value is based on chi-square test.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL